JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.25 CNY | -3.03% |
|
-5.09% | -2.75% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,898 | 5,427 | 5,134 | 4,423 | 4,301 | - |
| Enterprise Value (EV) 1 | 2,898 | 5,427 | 5,134 | 4,423 | 4,301 | 4,301 |
| P/E ratio | 40.2 x | 73.1 x | 50.9 x | 37.8 x | 30.6 x | 22.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 7.13 x | 6.12 x | 4.51 x | 3.59 x |
| EV / Revenue | - | - | 7.13 x | 6.12 x | 4.51 x | 3.59 x |
| EV / EBITDA | - | - | 29.8 x | 24.5 x | 16.4 x | 12.4 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 3.93 x | 2 x | 1.85 x | 1.74 x |
| Nbr of stocks (in thousands) | 308,688 | 308,796 | 346,665 | 419,611 | 419,611 | - |
| Reference price 2 | 9.388 | 17.57 | 14.81 | 10.54 | 10.25 | 10.25 |
| Announcement Date | 1/14/21 | 4/22/22 | 4/23/23 | 4/24/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 719.9 | 722.1 | 954.1 | 1,198 |
| EBITDA 1 | - | - | 172.4 | 180.8 | 262.6 | 348.2 |
| EBIT 1 | - | - | 106.3 | 112.2 | 150.5 | 207.3 |
| Operating Margin | - | - | 14.77% | 15.54% | 15.77% | 17.29% |
| Earnings before Tax (EBT) 1 | - | - | 106.1 | 112.5 | 149.6 | 203.3 |
| Net income 1 | 72.17 | 81.12 | 100.7 | 106 | 140.9 | 191.3 |
| Net margin | - | - | 13.98% | 14.68% | 14.76% | 15.96% |
| EPS 2 | 0.2338 | 0.2403 | 0.2908 | 0.2786 | 0.3350 | 0.4550 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/14/21 | 4/22/22 | 4/23/23 | 4/24/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 9.18% | 6.06% | 6.01% | 7.64% |
| ROA (Net income/ Total Assets) | - | - | - | - | 3.8% | 4.7% |
| Assets 1 | - | - | - | - | 3,707 | 4,070 |
| Book Value Per Share 2 | - | - | 3.770 | 5.260 | 5.550 | 5.900 |
| Cash Flow per Share 2 | - | - | 0.5600 | 0.3900 | 0.7000 | 0.9800 |
| Capex 1 | - | - | 310 | 214 | 187 | 168 |
| Capex / Sales | - | - | 43.11% | 29.69% | 19.6% | 14.02% |
| Announcement Date | 1/14/21 | 4/22/22 | 4/23/23 | 4/24/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.25
CNY
Average target price
9.3
CNY
Spread / Average Target
-9.27%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.75% | 596M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 300636 Stock
- Financials Jiangxi Synergy Pharmaceutical Co., Ltd.
